RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) shares traded up 0.4% during mid-day trading on Monday . The stock traded as high as $9.54 and last traded at $9.54. Approximately 1,009 shares traded hands during trading, a decline of 12% from the average session volume of 1,143 shares. The stock had previously closed at $9.50.
RemeGen Trading Up 0.4%
The business’s fifty day simple moving average is $10.58 and its 200-day simple moving average is $10.72.
RemeGen Company Profile
RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.
RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.
Further Reading
- Five stocks we like better than RemeGen
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
